"On behalf of our entire staff at Biocept, we congratulate Mark on receiving this well-deserved award in acknowledgement of his many contributions to the success of companies in the San Diego community," said Michael Nall, President and Chief Executive Officer of Biocept. "We are honored to have Mark serve as our senior financial executive at Biocept and have greatly benefitted from his experience and leadership."
Mr. Foletta was named Interim CFO of Biocept in August 2015. He previously served for nearly 13 years as Senior Vice President and CFO of Amylin Pharmaceuticals, where he was instrumental in negotiating that company's sale to Bristol-Myers Squibb Co. Prior to that, he was Senior Vice President and CFO of Triton Group Ltd. He currently serves as a director of AMN Healthcare, Dexcom and Regulus Therapeutics.
Biocept, Inc. is a commercial-stage molecular diagnostics company that utilizes a proprietary technology platform and a standard blood sample to provide physicians with important prognostic and predictive information to enhance individual treatment of patients with cancer. Biocept's patented technology platform captures and analyzes circulating tumor DNA, both in CTCs and in plasma (ctDNA). Biocept currently offers assays for gastric cancer, breast cancer, lung cancer, colorectal cancer, prostate cancer and melanoma, and plans to introduce additional CLIA-validated assays in the near term. For additional information, please visit www.biocept.com.
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability improve the detection and treatment of cancer and our plans to introduce additional CLIA-validated assays in the near term, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC's website located at www.sec.gov.
Logo - http://photos.prnewswire.com/prnh/20151013/276540LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biocepts-mark-foletta-honored-with-cfo-lifetime-achievement-award-300239894.html
SOURCE Biocept, Inc.